- Trials with a EudraCT protocol (94)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
94 result(s) found for: Montreal Cognitive Assessment.
Displaying page 1 of 5.
EudraCT Number: 2015-003188-13 | Sponsor Protocol Number: CONIVAD | Start Date*: 2016-09-23 | |||||||||||
Sponsor Name:AZIENDA OSPEDALIERO-UNIVERSITARIA CAREGGI | |||||||||||||
Full Title: Pilot study on the association choline alphoscerate-nimodipine in patients with subcortical vascular cognitive impairment | |||||||||||||
Medical condition: Subcortical vascular cognitive impairment | |||||||||||||
|
|||||||||||||
Population Age: Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-000762-29 | Sponsor Protocol Number: COLAL/11/2016 | Start Date*: 2017-10-09 | ||||||||||||||||
Sponsor Name:MDM S.P.A. | ||||||||||||||||||
Full Title: CHOLINA ALPHOSCERATE INJECTION VERSUS CITICOLINE INJECTION IN ELDERLY PATIENTS WITH COGNITIVE IMPAIRMENT RESULTING FROM CEREBROVASCULAR EVENT | ||||||||||||||||||
Medical condition: Cognitive impairment resulting from cerebrovascular event. | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: IT (Completed) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2022-001751-17 | Sponsor Protocol Number: IIBSP-DON-2022-43 | Start Date*: 2023-07-27 |
Sponsor Name:Institut de Recerca Hospital de la Santa Creu i Sant Pau - IIB Sant Pau | ||
Full Title: Multicenter, randomized, double-blind, placebo-controlled clinical trial evaluating the efficacy and safety of donepezil versus placebo in mild cognitive impairment associated with Parkinson's disease | ||
Medical condition: Parkinson's disease | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: ES (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2020-004864-25 | Sponsor Protocol Number: NN6535-4725 | Start Date*: 2021-04-29 | |||||||||||
Sponsor Name:Novo Nordisk A/S | |||||||||||||
Full Title: A randomised double-blind placebo-controlled clinical trial investigating the effect and safety of oral semaglutide in subjects with early Alzheimer´s disease (EVOKE plus) | |||||||||||||
Medical condition: Mild cognitive impairment (MCI) or mild dementia, both of the Alzheimer’s type | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Trial now transitioned) CZ (Trial now transitioned) DE (Trial now transitioned) FI (Trial now transitioned) IE (Trial now transitioned) SK (Trial now transitioned) NL (Trial now transitioned) AT (Trial now transitioned) BE (Trial now transitioned) SI (Trial now transitioned) DK (Trial now transitioned) GR (Trial now transitioned) PL (Trial now transitioned) PT (Trial now transitioned) BG (Trial now transitioned) IT (Trial now transitioned) FR (Trial now transitioned) ES (Ongoing) HR (Trial now transitioned) RO (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-000679-25 | Sponsor Protocol Number: IIBSP-CAN-2016-16 | Start Date*: 2016-05-31 |
Sponsor Name:INSTITUT DE RECERCA HSCSP | ||
Full Title: A prospective, randomized, double-blind and placebo-controlled, parallel group, phase II study to compare the efficacy and safety of candesartan versus placebo on cognitive impairment associated wi... | ||
Medical condition: Parkinson's Disease | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: ES (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2020-004848-29 | Sponsor Protocol Number: NN6535-4730 | Start Date*: 2021-04-29 | |||||||||||
Sponsor Name:Novo Nordisk A/S | |||||||||||||
Full Title: A randomised double-blind placebo-controlled clinical trial investigating the effect and safety of oral semaglutide in subjects with early Alzheimer´s disease (EVOKE) | |||||||||||||
Medical condition: Mild cognitive impairment (MCI) or mild dementia, both of the Alzheimer’s type | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Trial now transitioned) CZ (Trial now transitioned) DE (Trial now transitioned) FI (Trial now transitioned) IE (Trial now transitioned) SK (Trial now transitioned) NL (Trial now transitioned) AT (Trial now transitioned) BE (Trial now transitioned) SI (Trial now transitioned) DK (Trial now transitioned) GR (Trial now transitioned) PL (Trial now transitioned) NO (Trial now transitioned) PT (Trial now transitioned) BG (Trial now transitioned) IT (Trial now transitioned) FR (Trial now transitioned) ES (Ongoing) RO (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-001833-38 | Sponsor Protocol Number: 77347 | Start Date*: 2023-04-20 |
Sponsor Name:University Medical Center Groningen | ||
Full Title: The Dutch Parkinson GBA Ambroxol trial (DUPARG-AMBROXOL): A randomised, double-blind, placebo-controlled, single-center trial with Ambroxol in Parkinson patients with a GBA mutation. | ||
Medical condition: Parkinson's disease with a GBA1 mutation | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NL (Trial now transitioned) | ||
Trial results: (No results available) |
EudraCT Number: 2022-001453-23 | Sponsor Protocol Number: G-85974806 | Start Date*: 2023-01-12 |
Sponsor Name:ASATE | ||
Full Title: Pilot safety study of neoadjuvant radiotherapy in patients with glioblastoma. | ||
Medical condition: Glioblastoma | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: ES (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2021-004565-13 | Sponsor Protocol Number: GR-2018-12366771 | Start Date*: 2022-09-08 | |||||||||||
Sponsor Name:FONDAZIONE IRCCS ISTITUTO NEUROLOGICO CARLO BESTA | |||||||||||||
Full Title: Ambroxol as a disease-modifying treatment to reduce the risk of cognitive impairment in GBA-associated Parkinson's disease. A multicenter, randomized, double-blind, placebo-controlled, phase 2 trial. | |||||||||||||
Medical condition: Parkinson's disease associated to mutation on the GBA1 gene | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-004263-84 | Sponsor Protocol Number: CHUBX2017/29 | Start Date*: 2021-02-24 |
Sponsor Name:CHU de Bordeaux | ||
Full Title: AntiPlatelet theraPy stratEgy followiNg left atrial appenDAGe closurE | ||
Medical condition: Atrial Fibrillation, atrial appendage, anticoagulants, stroke, platelet aggregation inhibitors | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: FR (Trial now transitioned) | ||
Trial results: (No results available) |
EudraCT Number: 2021-003437-10 | Sponsor Protocol Number: CARTESIO | Start Date*: 2023-04-05 | |||||||||||
Sponsor Name:Azienda Socio Sanitaria Territoriale di Lodi | |||||||||||||
Full Title: PILOT STUDY ON THE EFFECTIVENESS OF CHOLINE ALFOSCERATE IN THE UNDER THRESHOLD DEPRESSION OF THE ELDERLY | |||||||||||||
Medical condition: Under threshold depression of the elderly. | |||||||||||||
|
|||||||||||||
Population Age: Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2022-003299-17 | Sponsor Protocol Number: 22-1005-CALCIFADE | Start Date*: 2023-03-20 | |||||||||||
Sponsor Name:University Medical Center Utrecht | |||||||||||||
Full Title: A randomized, placebo-controlled, double blind trial to study the effects of Etidronate on ectopic CALCIfication in FAhr’s Disease. | |||||||||||||
Medical condition: Fahr’s disease or sondrome is a neurodegenerative disease in which all patients present with bilateral vessel associated calcifications in the basal ganglia in the absence of other secondary causes... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-000755-97 | Sponsor Protocol Number: EPFL-CNBI-2017-01 | Start Date*: 2017-03-16 |
Sponsor Name:Defitech Chair in Brain-Machine Interface, EPFL | ||
Full Title: Brain-computer interface and neuromuscular stimulation for rehabilitation following chronic stroke | ||
Medical condition: I61 - Intracerebral haemorrhage I63 - Cerebral infarction Chronic condition (at least 10 months after occurrence of cerebrovascular accident) | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: Outside EU/EEA | ||
Trial results: (No results available) |
EudraCT Number: 2020-003796-17 | Sponsor Protocol Number: CST103/CST139-CLIN-010 | Start Date*: 2020-10-22 | ||||||||||||||||
Sponsor Name:CuraSen Therapeutics, Inc. | ||||||||||||||||||
Full Title: An Open-Label Brain Imaging and Cognition Study to Determine Changes in Cerebral Perfusion and Cognition After Oral Administration of CST-103 or CST-139 | ||||||||||||||||||
Medical condition: Patients with Mild Cognitive Impairment or Parkinson’s Disease | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2015-002145-63 | Sponsor Protocol Number: INMiND-02 | Start Date*: 2015-10-15 | |||||||||||
Sponsor Name:University of Southampton | |||||||||||||
Full Title: A double-blind, placebo-controlled study of the effect of a TNF alpha inhibitor, etanercept (Enbrel), on microglial activation in amyloid PET positive patients with Mild Cognitive Impairment due to... | |||||||||||||
Medical condition: Mild Cognitive impairment- due to Alzheimer's disease- intermediate likelihood | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-003254-17 | Sponsor Protocol Number: IIBSP-SAF-2017-75 | Start Date*: 2017-12-21 |
Sponsor Name:Institut de Recerca Hospital de la Santa Creu i Sant Pau | ||
Full Title: A 24-Week, Multicenter, Randomized, Double-blind, Placebo-Controlled, Add-on, Parallel-Group Study to Assess the Effect of Safinamide on Apathy in Patients With Parkinson's Disease | ||
Medical condition: Parkinson's disease | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: ES (Prematurely Ended) | ||
Trial results: (No results available) |
EudraCT Number: 2022-002266-33 | Sponsor Protocol Number: SATURN | Start Date*: 2022-10-10 |
Sponsor Name:BETH ISRAEL DEACONESS MEDICAL CENTER | ||
Full Title: STATINS USE IN INTRACEREBRAL HEMORRHAGE PATIENTS (SATURN) | ||
Medical condition: Intracerebral Hemorrhage (ICH) recurrence | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: ES (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2023-000127-36 | Sponsor Protocol Number: KIH22001 | Start Date*: 2023-04-04 | |||||||||||
Sponsor Name:Karolinska Institutet | |||||||||||||
Full Title: Evaluating rapamycin treatment in Alzheimer’s disease using positron emission tomography (ERAP) | |||||||||||||
Medical condition: Alzheimer's disease (AD) and mild cognitive impairment (MCI) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-001461-36 | Sponsor Protocol Number: CT-AMT-130-02 | Start Date*: 2021-06-30 | |||||||||||
Sponsor Name:uniQure biopharma B.V. | |||||||||||||
Full Title: A Phase Ib/II Randomised, Double-Blind Study to Explore Safety, Tolerability, and Efficacy Signals of Multiple Doses of Striatally-Administered rAAV5-miHTT Total Huntingtin Gene (HTT) Lowering Ther... | |||||||||||||
Medical condition: Huntington Disease | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: PL (Trial now transitioned) DE (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-001645-12 | Sponsor Protocol Number: ALPHA2PREVENT | Start Date*: 2021-06-28 |
Sponsor Name:Oslo University Hospital | ||
Full Title: Alpha 2 adrenergic receptor agonists for the prevention of delirium and cognitive decline after open heart surgery (ALPHA2PREVENT): randomised controlled trial. | ||
Medical condition: Postoperative delirium and cognitive decline in male and female participants aged 70+ scheduled for open heart surgery | ||
Disease: | ||
Population Age: Elderly | Gender: Male, Female | |
Trial protocol: NO (Trial now transitioned) | ||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
